Q1 EPS Forecast for Allarity Therapeutics Lifted by Analyst

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Equities research analysts at Ascendiant Capital Markets boosted their Q1 2026 earnings per share (EPS) estimates for Allarity Therapeutics in a research note issued on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.22) per share for the quarter, up from their previous estimate of ($0.24). Ascendiant Capital Markets has a “Buy” rating and a $9.75 price target on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($78.08) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.96) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.75.

Allarity Therapeutics Stock Performance

ALLR stock opened at $1.25 on Wednesday. The company has a market capitalization of $19.77 million, a price-to-earnings ratio of -1.56 and a beta of 0.01. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35. The stock has a fifty day moving average of $1.07 and a 200-day moving average of $1.18.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01.

Institutional Investors Weigh In On Allarity Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC bought a new position in shares of Allarity Therapeutics in the third quarter worth $441,000. Renaissance Technologies LLC raised its stake in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after purchasing an additional 181,426 shares during the period. DRW Securities LLC purchased a new stake in Allarity Therapeutics during the 4th quarter worth about $133,000. Capital Advisors Inc. OK purchased a new stake in Allarity Therapeutics during the 4th quarter worth about $108,000. Finally, Citadel Advisors LLC purchased a new stake in Allarity Therapeutics during the 3rd quarter worth about $149,000. Institutional investors own 11.53% of the company’s stock.

Key Allarity Therapeutics News

Here are the key news stories impacting Allarity Therapeutics this week:

• Positive Sentiment: Ascendiant raised its Q1 2026 EPS estimate to ($0.22) from ($0.24), a modest beat to the downside that suggests a slightly less negative near‑term cash burn view. Ascendiant raises Q1 2026 estimate
• Positive Sentiment: The firm also nudged FY2026 EPS to ($0.96) from ($0.97), a marginal improvement that supports the continuation of its Buy rating and $9.75 target — a factor likely supporting buying interest despite negative EPS. Ascendiant adjusts FY2026 estimate
• Neutral Sentiment: Ascendiant published a full slate of 2027 quarterly and FY estimates (each quarter ~($0.24); FY2027 ~$0.97 negative) — useful for modeling but not a material directional surprise versus its 2026 view. Ascendiant issues 2027 estimates
• Negative Sentiment: Ascendiant trimmed Q2, Q3 and Q4 2026 EPS estimates from ($0.24) to ($0.25) for each quarter, signaling slightly wider near‑term losses than previously expected — a potential headwind for sentiment if results track lower. Ascendiant trims several 2026 quarterly estimates
• Neutral Sentiment: Ascendiant kept a Buy rating and a relatively high $9.75 price objective, which supports upside narratives for long‑term investors but contrasts with the company’s negative EPS profile; note the report repeats a widely divergent “consensus” EPS figure (listed as ($78.08)), which appears anomalous and should be treated cautiously. Analyst rating and target reiterated

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.